Sertkaya, Zülfü10.07.20192019-07-1010.07.20192019-07-102016Sertkaya, Z. (2016). Re: Fascelli et al: Combined biparametric prostate magnetic resonance ımaging and prostate-specific antigen in the detection of prostate cancer: A validation study in a biopsy-naive patient population (urology 2016; 88:125-134). Urology, 95, 223-223. https://dx.doi.org/10.1016/j.urology.2016.04.011.0090-42951527-9995https://dx.doi.org/10.1016/j.urology.2016.04.011https://hdl.handle.net/20.500.12511/4048WOS: 000383698300057PubMed ID: 27112511I read with interest the article by Fascelli et al1The authorsaimed to validate the use of biparametric (T2- and diffusion-weighted) magnetic resonance imaging and prostate-specific antigen (PSA) or PSA density in a biopsy-naivecohort at risk for prostate cancer (PCa) and they used for-mulas for validation.eninfo:eu-repo/semantics/openAccessMortalityBiparametricProstateLetter9522322310.1016/j.urology.2016.04.011Q3Q1